Shattuck Labs, Inc. (STTK) · Aug 11, 2026 · Earnings

Phase 1 clears key safety hurdles; Phase 2 launch remains on track

Phase 1 clears key safety hurdles; Phase 2 launch remains on track

The quarter’s financial result was essentially in line with expectations. Shattuck reported a $0.12 per-share loss, matching the published consensus of roughly a $0.12 loss. There is no revenue, as expected for a clinical-stage biotech, while the larger share count helped reduce the reported per-share loss despite higher spending. (Income Statement)

$ millions, except per-share dataQ2 2026Q2 2025Change
Revenue$0.0$0.0— (Income Statement)
Research and development$11.7$8.7+35% (Income Statement)
General and administrative$4.5$4.4+2% (Income Statement)
Net loss$(15.2)$(12.5)22% larger loss (Income Statement)
Net loss per share$(0.12)$(0.24)Improved from dilution (Income Statement)
Cash and investments$208.3$78.1 at Dec. 31, 2025Higher after financing (Balance Sheet)

The meaningful new information is the Phase 1 readout for SL-325, not the income statement. The company reported a favorable safety profile, low-dose durability of DR3 blockade, no evidence of residual DR3 agonism, and what it describes as potentially best-in-mechanism immunogenicity. Those findings clear important development risks, but the filing provides topline claims rather than detailed patient-level efficacy data, so it does not yet establish clinical benefit. (SL-325 clinical update)

The development timeline remains intact rather than moving ahead of expectations. The Crohn’s disease Phase 2b trial is still expected to begin in the third quarter of 2026, while SL-846 toxicology data are expected at a medical conference in October. These are constructive execution updates, but they largely confirm the previously stated path rather than represent an accelerated milestone. (Recent business highlights; SL-846 program update)

Cash materially reduces near-term financing risk, although the improvement reflects capital raised rather than operating progress. Cash and short-term investments totaled approximately $208.3 million at June 30, and management says funding should extend into 2029. At the same time, research spending rose 35% year over year as the company advances toward Phase 2. (Balance Sheet; Financial Highlights; Income Statement) Net read: clinically encouraging and financially well funded, but the quarter itself was broadly expected and the decisive efficacy test remains ahead.

Original filing on SEC EDGAR

More Shattuck Labs, Inc. news

Phase 1 clears key safety hurdles; Phase 2 launch remains on track | STTK Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.